Melasma guide: causes, diagnosis, and the evidence-based treatment approach

Melasma is one of the most common and frustrating pigmentation conditions to treat — not because effective treatments don't exist, but because the condition is fundamentally recurrent. Understanding why melasma recurs, and why sun protection is as therapeutic as any depigmenting agent, is the foundation of effective long-term management. Here is the complete evidence-based guide.

What melasma is

Melasma is an acquired hypermelanosis — an increase in melanin production and distribution in the epidermis and/or dermis — producing brown to gray-brown macules and patches with irregular borders, predominantly on sun-exposed areas of the face:

Centrofacial pattern (most common): forehead, nose, cheeks, upper lip, chin
Malar pattern: cheeks and nose
Mandibular pattern: jawline (less common)

Who gets it: Melasma predominantly affects women (90–95% of cases); more common in Fitzpatrick skin types III–VI (though occurs in all skin types); highest prevalence in individuals of Latin American, Southeast Asian, Middle Eastern, and sub-Saharan African ancestry.

Pathophysiology: the dual trigger model

UV radiation

UV exposure is the primary and most universal trigger for melasma. The mechanisms are multiple:

Direct melanocyte stimulation: UVB and UVA directly stimulate tyrosinase activity and melanin synthesis via MITF (microphthalmia-associated transcription factor) upregulation
Keratinocyte-derived stimulation: UV-stressed keratinocytes release α-MSH (alpha-melanocyte stimulating hormone), endothelin-1, and stem cell factor (SCF) — all of which stimulate adjacent melanocytes
Reactive oxygen species: UV-generated ROS directly oxidize melanin intermediates and drive inflammatory melanogenesis
Plasmin pathway: UV activates the plasmin pathway (as described in the tranexamic acid guide) — increasing melanocyte stimulation via PAR-2 and prostaglandin signaling

Why SPF alone controls melasma: Even high-SPF sunscreen does not block 100% of UV. Melasma melanocytes are uniquely hyperreactive — they respond to sub-erythemal UV doses that normal melanocytes do not respond to. This is why even diligent SPF use may not be sufficient alone, and why shade + physical sun protection (hat, avoidance) matters beyond SPF.

Visible light: Emerging evidence suggests that visible light (400–700 nm) — particularly in the violet-blue range (400–450 nm) — also stimulates melanogenesis in darker skin types via opsin-3 in melanocytes. Standard chemical and mineral sunscreens do not filter visible light; only tinted mineral sunscreens containing iron oxides provide meaningful visible light protection. This may be relevant for treatment-resistant melasma in types IV–VI.

Hormonal triggers

Estrogen and progesterone stimulate melanocyte activity:

Oral contraceptive pills (OCP): Contain estrogen/progesterone → directly stimulate melanogenesis → one of the most common precipitants of new-onset melasma
Pregnancy: "Chloasma" (historical term for pregnancy melasma) — elevated estrogen and progesterone drive dramatic melanocyte activation in some women; typically improves postpartum
Hormone replacement therapy (HRT)

Mechanism: Estrogen receptors on melanocytes respond to estrogen by upregulating MITF and tyrosinase activity. Progesterone has separate but additive effects on melanogenesis.

The practical implication: If OCP is driving melasma, switching to a progestin-only method (IUD, progestin-only pill) may allow better treatment response — though this decision requires gynecological consultation.

Diagnosis: epidermal vs. dermal melasma

Wood's lamp examination

Under Wood's lamp (long-wave UVA, 365 nm):

Epidermal melasma: Melanin in the epidermis absorbs UVA → appears accentuated (darker/more sharply defined) under Wood's lamp
Dermal melasma: Melanin in the dermis does not accentuate → appears unchanged or less distinct under Wood's lamp

Clinical significance:

Epidermal melasma responds well to topical depigmenting treatments (tyrosinase inhibitors, cell turnover accelerators) — the melanin is in the target layer for topical penetration
Dermal melasma is significantly more difficult to treat — topical agents penetrate the epidermis but do not reliably reach melanin-laden macrophages in the dermis; laser treatments may be required
Mixed pattern is most common (the majority of melasma has both components)

Reflectance confocal microscopy (RCM)

Non-invasive optical technique that allows visualization of melasma at the cellular level without biopsy — demonstrates increased melanin in dermal macrophages (dermal component) and increased dendritic melanocytes in the epidermis (epidermal component). Used in research settings and increasingly in clinical practice for treatment planning.

The treatment hierarchy

Foundation: photoprotection (non-negotiable)

Daily broad-spectrum SPF 50+ is the cornerstone of melasma treatment — not an adjunct. Without consistent photoprotection, any depigmenting treatment will be overwhelmed by ongoing UV stimulation.

Tinted mineral SPF with iron oxides: For Fitzpatrick types III–VI, visible light filtering (iron oxides in tinted formulas) provides additional protection against the visible light melanogenesis pathway. Multiple studies confirm tinted SPF produces greater melasma improvement than untinted SPF of equivalent UV protection factor.

Physical sun protection: Wide-brimmed hat (blocks approximately SPF 5–15 additional depending on brim width), UV-protective clothing, shade-seeking — additive to sunscreen.

First-line: hydroquinone

Hydroquinone (HQ) remains the reference-standard depigmenting agent for melasma despite decades-old formulation. It inhibits tyrosinase as a substrate competitive inhibitor and at higher concentrations is cytotoxic to melanocytes.

Concentrations:

2%: Available OTC in the US; appropriate for mild melasma
4%: Prescription; the standard clinical concentration; significant superiority to 2% for moderate-to-severe melasma

Limitations:

Rebound hyperpigmentation on discontinuation (common)
Exogenous ochronosis with prolonged high-concentration use — particularly reported in African and African-American populations; rare at 4% for limited durations
Regulatory restrictions: banned or restricted OTC in EU, UK, and Australia due to safety concerns with prolonged use; available in some markets only by prescription

The modified Kligman triple combination

The most evidence-supported topical melasma formulation combines three complementary mechanisms:

Tri-Luma (4% hydroquinone + 0.05% tretinoin + 0.01% fluocinolone acetonide):

Hydroquinone: Tyrosinase substrate inhibition → reduces melanin synthesis
Tretinoin: Accelerates keratinocyte turnover → faster shedding of melanin-containing cells; also normalizes melanocyte function via RAR
Fluocinolone acetonide (low-potency corticosteroid): Reduces the irritation from HQ + tretinoin combination; some direct anti-inflammatory melanogenesis suppression

Taylor et al. (2003, Archives of Dermatology): Pivotal RCT of Tri-Luma vs. dual combinations (HQ + tretinoin, HQ + fluocinolone, tretinoin + fluocinolone) for melasma — triple combination produced significantly superior results to all dual combinations and vehicle at 8 weeks.

Second-line and combination approaches

Tranexamic acid (3–5% topical or 250 mg oral BID): Targets the plasmin/PAR-2 upstream pathway (complementary to HQ's tyrosinase inhibition); Lee 2020 JAAD RCT demonstrated 5% topical TA comparable to 3% HQ with fewer side effects; increasingly positioned as first-line for Fitzpatrick types V–VI where HQ risk/benefit is less favorable.

Azelaic acid 20%: FDA-approved for acne, with well-documented melasma activity (Baliña & Graupe 1991 Acta Derm landmark RCT — 20% AA equivalent to 4% HQ for melasma with fewer side effects); preferred for sensitive skin and patients with concurrent rosacea.

Alpha-arbutin (2–4%): OTC tyrosinase inhibitor with no ochronosis risk; appropriate for long-term maintenance after initial HQ-based clearance.

Niacinamide (5%): Melanosome transfer inhibition — covers a distinct step from tyrosinase inhibitors; additive in combination.

Chemical peels: Superficial glycolic acid peels (20–50%, series of 4–6) accelerate removal of melanin-containing corneocytes and enhance penetration of topical agents. Must be performed conservatively in darker skin types (risk of post-peel PIH paradox).

Laser and light (for refractory cases):

Q-switched Nd:YAG (1064 nm): Used for dermal melasma; shatters dermal melanin deposits; risk of rebound and post-inflammatory darkening — expertise required
Low-fluence Q-switched Nd:YAG "toning": Lower energy, multiple passes; gentler approach for difficult skin types
Fractional lasers: Higher risk of PIH; used selectively by experienced practitioners

Why melasma recurs and how to manage it

Melasma recurrence is the rule, not the exception — even after successful treatment. The underlying melanocyte hyperreactivity remains; UV exposure, hormonal changes, or skin inflammation will re-trigger pigmentation.

Long-term maintenance strategy:

Continue daily SPF 50+ (especially tinted for types IV–VI) indefinitely
Maintenance topical agents: Alpha-arbutin or niacinamide (rather than continuous HQ, which is not appropriate for indefinite use); low-dose retinol for ongoing cell turnover
Tranexamic acid (oral or topical) for chronic maintenance — favorable long-term safety profile
Hormonal modification: If OCP is identified as a contributing factor, discuss alternatives with gynecologist
Seasonal awareness: Melasma typically worsens in summer — increase photoprotection, consider brief treatment cycles with prescription agents in spring

Looking for a skincare or pigmentation consultation? Browse med spa providers on MedSpot →